Biogen Agreement Further Validates Anavex Life Sciences (AVXL) AV2-73 - FBR

September 28, 2016 10:39 AM EDT
Get Alerts AVXL Hot Sheet
Price: $3.29 --0%

Rating Summary:
    1 Buy, 0 Hold, 0 Sell

Rating Trend: Up Up

Today's Overall Ratings:
    Up: 1 | Down: 2 | New: 2
Trade AVXL Now!
Join SI Premium – FREE

Get inside Wall Street with StreetInsider Premium. Claim your 2-week free trial here.

FBR Capital analyst Christopher James weighed in on Anavex Life Sciences (NASDAQ: AVXL) after the company announced that it has signed a material transfer agreement with Biogen under which Biogen will test AV2-73 in a validated preclinical CNS assay. As a reminder, AV2-73 is a sigma-1 receptor antagonist with potential to promote recovery of motor function and reactivation of neuroplasticity in patients suffering from neurocognitive diseases.

James commented, "We believe these early studies could lead to its advancement into other neurodegenerative and demyelination diseases such as Parkinson's disease and multiple sclerosis. We view this agreement with BIIB as additional validation for AV2-73's potential in multiple CNS-related disorders, but remain focused on the development plan for the Phase II study with AV2-73 in Rett syndrome, an orphan disease with no approved therapies."

The firm maintained an Outperform rating and price target of $10.00

For an analyst ratings summary and ratings history on Anavex Life Sciences click here. For more ratings news on Anavex Life Sciences click here.

Shares of Anavex Life Sciences closed at $3.14 yesterday.

Serious News for Serious Traders! Try Premium Free!

You May Also Be Interested In

Related Categories

Analyst Comments, FDA, Momentum Movers, Trader Talk

Add Your Comment